FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus

One of the critical path initiatives of the Food and Drug Administration (FDA) is to accelerate the development and availability of a safe and effective artificial pancreas for the treatment of diabetes mellitus. The FDA has established a multidisciplinary group of scientists and clinicians, in partnership with the National Institutes of Health (NIH), to address the clinical, scientific and regulatory challenges related to this unique medical product.

Section editor:Janet Woodcock – Food and Drug Administration, Rockville, MD, USA